| Quick Answer |
| The prescription medicines in India with direct evidence for appetite control are GLP-1 based: semaglutide (sold as Wegovy, and as Ozempic for diabetes) and tirzepatide (Mounjaro), which also acts on a second gut hormone, GIP. In trials they reduced how much people ate and eased cravings. Both are prescription only, and in India they are meant to be prescribed by specialist doctors and used under medical supervision. |
Why Appetite Matters for Weight Loss
Ask anyone who has tried to lose weight what broke the plan, and the answer is rarely a lack of information. It is the 5 pm pull towards chai and namkeen, or the mithai box doing the rounds at office.
That pull comes from hormones and brain circuits that guard your body weight. When you eat less, they push back with stronger hunger, which is why willpower alone tends to fade by week six.
In India the need is large. The ICMR-INDIAB study, which surveyed over 1.1 lakh adults across 31 states and union territories, found generalised obesity in 28.6% and abdominal obesity in 39.5% of Indian adults. It used Asian cut-offs: a BMI of 25 for obesity, and a waist of 90 cm in men or 80 cm in women.
So a weight loss medicine for appetite control is solving the part of the problem people find hardest to manage alone.
How Appetite-Controlling Medicines Work (GLP-1 & GIP, gut–brain axis)
GLP-1 is a hormone your gut releases after you eat. It slows how fast food leaves the stomach and reduces food intake by acting on the brain.
Your own GLP-1 is broken down within minutes. The medicines are modified versions built to last for days, so the fullness signal keeps working between meals. This message from gut to brain is what doctors call the gut–brain axis.
That also answers a common search, how does Ozempic work. Ozempic and Wegovy contain the same molecule, semaglutide. Ozempic is approved for type 2 diabetes and Wegovy for weight management.
The appetite effect has been measured directly. In a 20-week trial by Friedrichsen and colleagues, adults with obesity on weekly semaglutide ate 35% less at a free-choice lunch than those on placebo, and reported fewer cravings and better control over eating.
Tirzepatide adds GIP to the mix. In a Diabetes Care trial by Heise and colleagues, tirzepatide and semaglutide cut appetite by similar amounts, yet tirzepatide produced more weight and fat loss. The researchers said meal intake alone could not explain the gap.
Medications Available in India
CDSCO has approved three medicines for obesity and weight management: orlistat, semaglutide and tirzepatide. All three need a prescription.
In March 2026, the ministry reiterated through a PIB release that GLP-1 medicines are approved on the condition that endocrinologists and internal medicine specialists prescribe them, and cardiologists for some indications.
Semaglutide (injectable & oral)
Semaglutide for weight management is a once-weekly injection. Its Indian patent expired in March 2026, and several generic versions have since been approved under the same prescription rules.
There is also a daily tablet. In India, oral semaglutide has mainly been used for type 2 diabetes, while in the US a higher-dose tablet was added to the Wegovy prescribing information for weight management. The tablet has a fussy routine: an empty stomach, a small sip of water, and a 30-minute wait before chai or breakfast.
In the STEP 1 trial and the tirzepatide SURMOUNT-1 trial, adults using these medicines alongside lifestyle changes lost up to 20% of their body weight.
Tirzepatide
Tirzepatide is a once-weekly injection sold in India as Mounjaro. A single molecule, it activates both GIP and GLP-1 receptors, as its US prescribing information describes.
On Mounjaro vs Wegovy, the large head-to-head SURMOUNT-5 trial found tirzepatide produced greater average weight and waist reduction than semaglutide over 72 weeks.
The better fit for you depends on your health history and how you tolerate each medicine, which is a call for your doctor.
Older/other options
Orlistat is the oldest approved option, and it does nothing for appetite. It blocks the enzyme that digests fat, so part of the fat you eat passes out unabsorbed, as the four-year XENDOS study describes. With ghee-rich meals, oily stools are a common complaint.
Liraglutide, an earlier daily GLP-1 injection, is used in India for type 2 diabetes but is not on the government’s list of approved weight management medicines.
Older appetite suppressants that acted on brain chemicals have a poor record. Sibutramine was withdrawn in 2010 after the SCOUT trial found more heart attacks and strokes in people with existing heart disease.
Comparison Table
| Medicine | Effect on appetite | How it is taken | Status in India |
| Semaglutide (Wegovy; Ozempic for diabetes) | Acts on GLP-1; lowered meal intake and cravings in trials | Weekly injection; daily tablet | Approved for weight management; specialist prescription |
| Tirzepatide (Mounjaro) | Acts on GLP-1 and GIP; appetite reduction similar to semaglutide in one trial | Weekly injection | Approved for weight management; specialist prescription |
| Orlistat | No direct effect; blocks fat absorption | Capsule with meals | Approved for weight management |
| Liraglutide | Acts on GLP-1 | Daily injection | Used for type 2 diabetes; not on the weight management list |
| Sibutramine | Acted on brain chemicals | Tablet | Withdrawn in 2010 |
‘Food Noise’ Explained
Food noise is the constant mental chatter about food that some people live with. Penn State researchers, in a Nutrients review by Hayashi and colleagues, describe it as a heightened reaction to food cues that leads to intrusive thoughts and eating you did not plan.
In an Indian home it sounds familiar. Lunch is over, yet the leftover gulab jamun in the fridge keeps returning to mind through a work call. Festive season turns the volume up, with dabbas of kaju katli arriving from every neighbor.
Many people on GLP-1 medicines say this chatter goes quiet. Still, food noise has no agreed clinical measure yet, and the Hayashi review notes that most reports linking GLP-1 appetite effects to quieter food noise are anecdotal.
Side Effects & Who Shouldn’t Use Them
The common side effects are digestive: nausea, diarrhea, vomiting, and constipation. In SURMOUNT-5, they were mostly mild to moderate and occurred during the weeks when the dose was being raised.
Pancreatitis and gallbladder disease are rarer but serious, and the Wegovy prescribing information lists both. A sudden severe pain in the upper abdomen needs a doctor that day.
These medicines are not for anyone with a personal or family history of medullary thyroid cancer or the inherited condition MEN 2. The tirzepatide label advises stopping once a pregnancy is recognized and does not recommend it with severe gastroparesis, and doctors take extra care with anyone who has had pancreatitis.
Why Supervision Matters
India’s regulator has been unusually direct. The March 2026 PIB release reported audits of 49 entities, including online pharmacy warehouses and slimming clinics, after GLP-1 medicines started moving without proper prescriptions.
A supervising doctor does what a pharmacy counter cannot. They read your weight against Indian cut-offs (BMI 23 for overweight, 25 for obesity, waist 90 cm or 80 cm), screen your thyroid and pancreatic history, and raise the dose slowly so side effects stay manageable.
Smaller appetite also means smaller meals, and protein can fall short. The Dietary Guidelines for Indians advise getting good-quality protein from a variety of foods, and the Indian Food Composition Tables 2017 have long recorded pulses as rich protein sources.
So the katori of dal earns its place on a GLP-1 plate. A registered dietitian can shape the rest to fit your routine.
| Conclusion |
| Appetite is the hardest part of weight loss to manage alone, and GLP-1 based medicines are the prescription options in India with direct evidence for reducing it. Semaglutide and tirzepatide lowered meal intake in trials, orlistat works on fat absorption instead, and older brain-acting suppressants were withdrawn. All of them belong under a specialist’s care, available as a part of MetaGO’s program, with protein-aware eating and a plan for the long term. |
FAQs
Which prescription medicines help control appetite?
In India, the prescription medicines with direct appetite evidence are semaglutide and tirzepatide. Both reduced how much people ate in clinical trials. Orlistat, the third approved option, works on fat absorption rather than appetite. All need a prescription from a specialist doctor.
How does a GLP-1 medicine reduce hunger?
It copies GLP-1, a gut hormone released after meals. The medicine signals fullness to the brain’s appetite centers and slows how fast the stomach empties, and it lasts for days instead of minutes. In one trial, people on semaglutide ate 35% less at a free-choice meal than those on placebo.
What is ‘food noise’?
Food noise is the steady stream of intrusive thoughts about food, such as the sweets in the cupboard or the next snack. Researchers link it to heightened reaction to food cues. Many GLP-1 users report it quietens, though this evidence is still mostly anecdotal.
Are over-the-counter appetite suppressants safe?
Over-the-counter appetite suppressant products are sold as food supplements, and none is among the three medicines CDSCO has approved for weight management. Their label claims have not gone through drug approval. The last brain-acting prescription suppressant widely used in India, sibutramine, was withdrawn in 2010 over heart risks.
Does appetite come back after stopping?
Usually, yes, because the effect fades once the medicine leaves the body. In the STEP 1 extension, people who stopped semaglutide regained about two-thirds of the weight they had lost within a year, and the SURMOUNT-4 trial saw substantial regain after stopping tirzepatide. Plan any stop with your doctor.
| Medical Disclaimer |
| This article is for general education and is not medical advice, diagnosis, or a prescription. Semaglutide, tirzepatide, and orlistat are prescription-only medicines in India. Do not start, change, or stop any medicine without consulting a qualified doctor who can assess your health history. |
